3B Blackbio Dx Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from 3B Blackbio Dx Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Shareholder Slice Ratio: Share count rose 14% in 3 years, so each share's slice of the company became smaller. Dividends paid equalled 6% of profit over the same period. Bigger rise in share count than 88% of Healthcare companies in India.
- Self-Funding Ratio: Over the last 3 years its own operating cash covered its investment spending (capex) 4.6 times. Higher than 88% of Healthcare companies in India.
- Growth Efficiency Ratio: Sales grew 130% in 3 years; of every extra ₹100 of sales, ₹42 became extra profit. Higher than 88% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹87Over the last 3 years, every ₹100 of reported profit came with ₹87 of operating cash.
Lower than 64% of Healthcare companies in India.
Self-Funding Ratio
4.6×Over the last 3 years its own operating cash covered its investment spending (capex) 4.6 times.
Higher than 88% of Healthcare companies in India.
Cash Locked Ratio
₹39For every ₹100 of sales, ₹39 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹61 tied up three years earlier.
More money tied up than 76% of Healthcare companies in India.
Growth quality
Steadiness Ratio
3/3 · 3/3Sales and profit both grew in each of the last 3 years.
Steadier than 83% of Healthcare companies in India.
Growth Efficiency Ratio
₹42Sales grew 130% in 3 years; of every extra ₹100 of sales, ₹42 became extra profit.
Higher than 88% of Healthcare companies in India.
Asset Productivity Ratio
+130% / +77%In 3 years sales changed by +130% while total assets changed by +77%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
No debt dueNo debt falls due within a year, according to the latest yearly balance sheet.
Cash Cushion Ratio
+8%Cash, after subtracting all debt, equals 8% of its market value (net cash).
Higher than 88% of Healthcare companies in India.
Tangible Assets Ratio
98%Of every ₹100 the company owns, ₹98 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 56% of Healthcare companies in India.
Tangible Net Worth Ratio
98%Of every ₹100 of net worth, ₹98 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 59% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
3B Blackbio Dx Limited owes ₹0.12 for every ₹1 it owns. Net profit rose 26% in the year to Mar 2026, and grew 32% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
20.5Investors pay ₹20.5 for every ₹1 of 3B Blackbio Dx Limited's yearly profit, lower than 82% of Healthcare companies in India.
P/B ratio
3.57The share price is 3.57 times 3B Blackbio Dx Limited's book value per share, lower than 65% of Healthcare companies in India.
Market cap
₹1,158 CrThe total market value of all of 3B Blackbio Dx Limited's shares at today's price (share price × number of shares), smaller than 78% of Healthcare companies in India. PosiCap size class: Mini Cap.
Net worth (book value)
₹324 CrWhat 3B Blackbio Dx Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹377.95Net worth divided by the number of shares. The share price of ₹1,349 is 3.6 times this, which is the P/B above.
Return on equity (ROE)
16.9%3B Blackbio Dx Limited earned 16.9% on its shareholders' money over the last year, higher than 66% of Healthcare companies in India.
Owes vs Owns
0.12×3B Blackbio Dx Limited owes ₹0.12 for every ₹1 it owns (low), lower than 96% of Healthcare companies in India.
Dividend yield
0.34%3B Blackbio Dx Limited pays 0.34% of its share price as dividends a year, lower than 53% of dividend-paying Healthcare companies in India.
Revenue growth
+47%Revenue rose 47% in the year to Mar 2026, and grew 32% a year on average over 3 years.
Profit growth
+26%Net profit rose 26% in the year to Mar 2026, and grew 32% a year on average over 3 years.
Profit margin
42.2%3B Blackbio Dx Limited keeps ₹42 of every ₹100 of revenue as net profit.
Cash quality
0.9×Cash from 3B Blackbio Dx Limited's business was 0.9× its reported profit in the year to Mar 2026 — less cash came in than the profit reported.
Interest cover
232.7×3B Blackbio Dx Limited's operating profit covered its interest costs 232.7 times in the year to Mar 2026.
Cash vs debt
Net cash3B Blackbio Dx Limited held ₹95 Cr more cash than debt (net cash) at Mar 2026.
Questions
What is 3B Blackbio Dx Limited's P/E ratio?
Investors pay ₹20.5 for every ₹1 of 3B Blackbio Dx Limited's yearly profit, lower than 82% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For 3B Blackbio Dx Limited: ₹1,158 Cr ÷ ₹324 Cr (31 Mar 2026) = 3.6.
What is 3B Blackbio Dx Limited's return on equity?
3B Blackbio Dx Limited earned 16.9% on its shareholders' money over the last year, higher than 66% of Healthcare companies in India.
How much does 3B Blackbio Dx Limited owe compared with what it owns?
3B Blackbio Dx Limited owes ₹0.12 for every ₹1 it owns (low), lower than 96% of Healthcare companies in India.
Does 3B Blackbio Dx Limited pay a dividend?
Yes. 3B Blackbio Dx Limited pays 0.34% of its share price as dividends a year, lower than 53% of dividend-paying Healthcare companies in India.
Is 3B Blackbio Dx Limited's revenue growing?
Revenue rose 47% in the year to Mar 2026, and grew 32% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.